Field Medical Advisor Hematology

Field Medical Advisor Hematology

Reports to Country Medical Lead Switzerland

50% field based

Are looking for an exciting opportunity where you can leverage your medical affairs expertise

?In an environment where your impact is instantly visible

?This role is a rare chance to be part of a small, highly motivated team, tasked with delivering results and given the autonomy to define how they are achieved. How does that sound to you

?We are looking for individuals who relish the responsibility of playing an important medical role in a country medical function, but who wish to maintain their connectivity with healthcare professionals through field-based interactions

.It is a unique opportunity to shape the landscape and the organization and grow alongside the company as it develops

.As a medical and scientific expert for Switzerland you will be significantly contributing to the launch planning and execution with a cross-functional team in the Hematology business. You will work closely with key external stakeholders and have a direct reporting line to the Country Medical Lead Switzerland

.
It is an exciting time in the company’s development and an excellent opportunity for individuals joining us to contribute to building and shaping Menarini-Stemline’s Hematology / Oncology business. Check out the company profile at the botto

m.
Primary Responsibilit

ies
● Works closely with the Country Medical Lead, the DACH Medical team as well as the Swiss Commercial team to establish a medical footprint in Switzerl

and.● Establishes, develops-and manages collaborative relationships with key medical experts and opinion leaders in Switzerland in the field of Hemato-Oncology in disease areas relevant for Steml

ine.● Where appropriate or relevant gives strategic guidance drives and is hands-on, in the structured tactical execution of all local medical activities, in close collaboration with Medical Affairs Eur

ope.● Leads, coordinates and pro-actively contributes to all pre-launch activities for Hemato-Oncology compounds and indications in Switzerl

and.● Locally facilitates patient access programs to address high unmet medical ne

eds.● Provides medical expertise in regulatory and reimbursement approval processes within Switzerl

and.● Partners with Clinical Development and Clinical Operations to identify and work with local opinion leaders, investigators, and clinical experts in Switzerland that support the development of new compounds and indicat

ions● Ensures all activities required by pharmacovigilance and risk management are planned, set-up and pursued in accordance to respective local and EU

laws● Ensures legal excellence and compliance in all medical activities as per Stemline SOPs and local regulat

ions
Desired Skills, Experience, and Attri

butes
● Experienced & senior Medical Advis

or/MSL● Previous experience of product launches in Hemato-Oncology is d

esired● Substantial experience in Hemato-Oncology with established network to key experts in Switzerland is pref

erred.● Doctorate degree (PhD, PharmD, MD) with at least 5 years of relevant industry experience is re

quired● Mobile, willing to travel (approx. 50 % work in

field)● Entrepreneurial spirit and self-driven perso

nality● Passion about strategic launch planning and execution as well as track record in developing and executing successful (pre-)launch initi

atives● Proven basic science and/or clinical background to enable engagement of internal and external stakeholders in a scientifically meaningful ex

change● Ability to work independently in a fast-paced environment, to anticipate and adapt to

change● Excellent written and oral communication skills and ability to engage in collaborative decision

making● Fluent in German and English. French is an

asset.● Passionate about making a meaningful difference for patients and care

givers
Menarini / Stemline is an equal opportunity employer. We celebrate diversity and are committed to creating an inclusive environment for all em

ployees
Founded in 1886 in Naples under the name of Farmacia Internazionale, Menarini moved in 1915 to Florence where the Group’s headquarters are still located today. High quality therapeutics and diagnostics solutions for patients, ethics as our underlying principle, dedication to innovation and advancement, strong people centricity and environmental sustainability. These five pillars form the foundation of the Menarini Group, an Italian pharmaceutical company with nearly 135 years of

history.
The Menarini Group is present in 70 countries and our products are sold in 140 locations around the world. Its companies span from Europe to Asia, to Africa and the Middle East, to Central America and to the United States where with the acquisition of Stemline Therapeutics, a NASDAQ-listed biopharmaceutical company, the company marked its entry into the US oncolog

y market.
Thanks to the valuable contribution of around 18,000 employees, every year more than 500 million packs of drugs are produced at the Group's 18 manufacturing sites including a biotech plant for the manufacturing of monoclonal antibodies that also serves external clients distributed across 6 c

ontinents.Menarini has made a strong commitment to oncology, investing in a pipeline of five investigational compounds for the treatment of a variety of haematological and solid tumours. The acquisition of Stemline Therapeutics in June 2020, further strengthened Menarini’s oncology portfolio, adding both commercial and clinical-stage assets. Tagraxofusp is a novel, first in class targeted therapy for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) and to date, the only approved treatment for BPDCN in the U.S. and EU, and the first and only approved CD123-targeted therapy. Tagraxofusp is also being evaluated as both a single agent and in combination, in other CD123+ indications, including acute myeloid leukaemia (AML), chronic myelomonocytic leukaemia (CMML), and myelofibr

osis (MF).Additionally, Menarini received exclusive rights to commercialise Selinexor for the treatment of oncology indications in the European Union and other European countries (including the United Kingdom), Latin America and other key countries. Menarini has signed an exclusive licensing agreement with Karyopharm Therapeutics for the rights to commercialise an innovative therapeutic option in Europe, Latin America, Turkey, Russia, and CIS countries. Selinexor is a first-in-class, oral Selective Inhibitor of Nuclear export compound for the treatment of hematologic cancers and solid tumours. It is already marketed in the US for multiple myeloma and is under development for solid tumour indications. Selinexor is registered in the EU for both early and l

ate lines.
Menarini entered into a global licence agreement with Radius Health to complete the development of Elacestrant, an oral SERD in late-stage Phase 3 development for hormone receptor-positive advanced breast cancer. Following a successful phase 3 study, Menarini Stemline received FDA approval in January 2023 under priority review and successfully oversaw a strong launch in February to the US market with the EMA review process concluded positively in Sept

ember 2023.Menarini’s commitment to oncology is also reflected in the investments made in the liquid biopsy diagnostic field through its affiliate Menarini Silicon Biosystems (MSB), a pioneer in rare cell analysis and non-invasive, advanced diagnostic solutions. MSB’s CELLSEARCH Circulating Tumour Cell (CTC) Test is the first and only clinically validated blood test cleared by the U.S. Food & Drug Administration (FDA) for detecting and counting CTCs in metastatic breast, prostate, and colorectal cancer when used in conjunction with other clinical monitori

ng methods.Since 2021, MSB has offered in the US a menu of non-invasive Laboratory Developed Tests (LDTs) provided through its CLIA/CAP accredited US-based Lab. The services include CMC enumeration, CTC enumeration and PDL-1/HER2 biomarker and offer a minimally invasive approach to follow cancer patient’s therapeut

ic journey.
In 2022, the company launched the CELLSEARCH® Circulating Multiple Myeloma Cell (CMMC) Enumeration LDT, the first-of-its-kind, which directly measures levels of plasma cells in the blood of patients. This test provides new, complementary information to that of the bone marrow biopsy and other standard-of-care measures. Due to its minimally invasive nature, it can be performed serially to assess plasma cell burden without requiring repeated bone marr

ow biopsies.
Menarini's vision and uniqueness in oncology is to bring together innovative therapeutic solutions and advanced liquid biopsy-based diagnostics for faster, more effective and precise patien

t management.
It is an exciting time in the company’s development and an excellent opportunity for individuals joining us to contribute to building and shaping Menarini Stemline’s Onco